Abstract: Tuft cells are solitary chemosensory epithelial cells with microvilli at the top, which are found in hollow organs such as the gastrointestinal tract, pancreas, and lungs. Recently, an increasing number of studies have revealed the chemotactic abilities and immune function of the tuft cells, and numerous efforts have been devoted to uncovering the role of tuft cells in tumors. Notably, accumulating evidence has shown that the specific genes (POU2F3, DCLK1) expressed in tuft cells are involved in vital processes related with carcinogenesis and cancer development. However, the interaction between the tuft cells and cancer remains to be further elucidated. Here, based on an introduction of biological functions and specific markers of the tuft cells, we have summarized the functional roles and potential therapeutic implications of tuft cells in cancers, including pancreatic cancer, lung cancer, gastric cancer, colon cancer, and liver cancer, which is in the hope of inspiring the future research in validating tuft cells as novel strategies for cancer therapies.
Introduction
Tuft cells, once biological enigmas, are rare chemosensory epithelial cells characterized by unique apical microvilli. While long known for their role in sensing parasites and initiating Type 2 immune responses (the "weep and sweep" response), recent research has unveiled their significant influence on the tumor microenvironment. This review synthesizes current knowledge on how tuft cells drive specific subtypes of lung, pancreatic, and gastrointestinal cancers, identifying master regulators like POU2F3 and DCLK1 as promising therapeutic targets.
Origins and Differentiation
Tuft cells originate from Lgr5+ crypt base columnar (CBC) stem cells. Their differentiation is governed by a specific hierarchy of transcription factors. As shown in Figure 4, the lineage involves the suppression of HES-1 and the activation of ATOH1 and POU2F3. POU2F3, in particular, is the master regulator of tuft cell identity across various organs including the stomach, lungs, and intestines. Understanding this lineage is crucial, as these differentiation pathways can be hijacked during oncogenesis.
Chemosensory Signaling and the Immune Niche
Tuft cells act as "sentinels," using G-protein coupled receptor (GPCR) signaling to detect environmental cues such as succinate from helminths or protists. This signaling cascade, involving GNAT3, PLCβ2, and TRPM5, leads to the release of IL-25 and Acetylcholine (ACh). IL-25 activates type 2 innate lymphoid cells (ILC2s), which secrete cytokines like IL-13 to promote epithelial remodeling. This neuro-epithelial crosstalk is a hallmark of tuft cell function and plays a significant role in shaping the tumor niche.
Tuft Cells in Specific Malignancies
Lung Cancer
In Small Cell Lung Cancer (SCLC), a distinct "tuft-like" subtype has been identified, defined by high POU2F3 expression. These tumors are highly proliferative and entirely dependent on POU2F3 for survival. Silencing this transcription factor in cell lines leads to dramatic growth inhibition, marking it as a high-value therapeutic "Achilles' heel."
Gastric and Pancreatic Cancer
In gastric cancer, tuft cells are a primary source of Acetylcholine (ACh), which stimulates Nerve Growth Factor (NGF) expression in the epithelium, creating a feed-forward loop that promotes cancer progression. In the pancreas, tuft cells increase during early injury (acinar-to-ductal metaplasia) to fight inflammation, though they are often absent in invasive disease, suggesting a complex, stage-dependent role.
Colon Cancer
The marker DCLK1 identifies a population of tuft cells that act as quiescent progenitors. These cells can "wake up" following injury to drive regeneration, but they can also be hijacked to become cancer-initiating cells. Specific ablation of DCLK1+ tumor stem cells has been shown to lead to significant regression of polyps in mouse models without damaging the normal healthy intestine.
Conclusion and Future Directions
The discovery of tuft cell heterogeneity (tuft-1 vs. tuft-2) and their organ-specific roles provides a new framework for cancer research. While mouse models and single-cell RNA sequencing (scRNA-seq) have provided deep mechanistic insights, human validation remains the next major hurdle. Developing safe, bioavailable inhibitors, such as DCLK1-IN-1, could offer a new frontier for targeted cancer therapies that spare healthy tissue.
Summary updated